Abstract
A 40-Hz white light emitting diode (WLED) has emerged as an alternative nonpharmacological and noninvasive approach to Alzheimer disease (AD). Here, we investigated the therapeutic effects of 40-Hz WLED on psychiatric symptoms (PS) and the contribution of mitochondrial factors in the early stages of sporadic AD (sAD) in rats. In male Wistar rats, the AD model was induced via intracerebroventricular (ICV) injection of streptozotocin (STZ). After recovering (7 days) from stereotaxic surgery, 40-Hz WLED exposure was performed for 7 consecutive days lasting 15 min/d. Behavioral (elevated plus maze (EPM), force swim test, and social interaction test), enzymatic, and molecular assays were conducted 24 hours after the last 40-Hz WLED exposure. Behavioral tasks revealed that 40-Hz WLED exposure in STZ-induced toxicity rats lowered anxiety and depression and increased social interaction. Furthermore, the 40-Hz WLED therapy in STZ-induced toxicity rats increased catalase (CAT) activity in the amygdala, decreased the activity of monoamine oxidases A and B in the whole brain, and increased mitochondrial DNA in the hippocampus. The current study supports that 40-Hz WLED therapy improved PS and biomarkers in the early stages of sAD. Also, a potential relationship between PS and alterations in mitochondrial markers in certain brain regions seems to exist.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
